Developer docs
API playgroundTry for free, no card

Search company profiles

Aurora Pharmaceutical

Full company profile

uuid00095bs

Namestring
Aurora Pharmaceutical
Legal namestring
Aurora Pharmaceutical, Inc.
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Aurora Pharmaceutical, Inc. is a privately-held veterinary pharmaceutical manufacturer headquartered at 1196 Highway 3 South, Northfield, Minnesota, that develops, manufactures, and distributes FDA-approved generic and branded animal health products across six species verticals: equine, porcine, poultry, bovine, companion animals, and a small human health line. The portfolio spans six therapeutic categories — antibiotics (e.g., EQUISUL-SDT®, TiaGard® 12.5%), pain management (EquiCoxib™/firocoxib), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. jelly), wound care and antiseptics (BARRIER® Wound Care, PRO-TEC® chlorhexidine cleansers), and stress/hydration supplements (BALANCE, ORAL-PRO® D3/E, oregano). The company operates GMP-certified manufacturing at its single Northfield facility and explicitly positions around first-generic FDA approvals (DectoGard as the first generic doramectin topical solution; EquiCoxib as the generic equivalent to EQUIOXX® Paste) and affordable alternatives to brand-name veterinary drugs.

The business model is direct-to-customer via an authorized field sales representative network that calls on livestock producers, veterinarians, and pet owners, supplemented by a self-serve VET PORTAL for veterinary professionals and phone/email ordering for smaller accounts. Products are sold primarily in the United States with differentiated labeling for international markets, and pricing is not publicly disclosed — customers must contact sales — but the company's value proposition centers on competitive pricing of FDA-approved formulations against branded incumbents. Customer segments are diversified across commercial livestock (beef, dairy, swine, poultry), the equine show/performance industry, companion animal owners and veterinary clinics, and a minor human health line (Oral-Pro® Pyrantel Pamoate).

Underlying technology is conventional small-molecule veterinary pharmaceutical formulation and manufacturing rather than biologs or novel modalities; proprietary features are described as advanced green formulation/delivery systems, multi-species formulation expertise, and quality-controlled manufacturing. Aurora has launched four products in 2024 (DectoGard, EquiCoxib, KLENTZ, TiaGard 12.5%), with leadership in place under CEO/President Michael Strobel and CFO Lori Happel, ~$7.46M in cumulative disclosed equity funding (2011 and 2015 rounds), 11–50 employees, and a stated DVM Student Scholarship Program scaling from $75K (2023) to $100K (2026).

Short descriptiontext

Aurora Pharmaceutical is a private, GMP-certified veterinary pharmaceutical manufacturer in Northfield, Minnesota that develops, produces, and sells FDA-approved generic and branded animal health products — including antibiotics, parasiticides, NSAIDs, reproductive drugs, wound care, and supplements — across equine, bovine, porcine, poultry, companion animal, and limited human markets in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNorthfield, United States
HQ citystring
Northfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, animal health products, livestock medications, pet parasiticides, FDA-approved generics
Industry4 codes
PRIMARYHLAMAEAM
Generic & Private-Label Veterinary Pharmaceuticals
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAF
Pain Management, Anesthesia & Critical Care Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYCRAOAKAD
Pet Pharmaceuticals & Veterinary Supply Distribution
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Veterinary Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Veterinary Pharmaceutical Products
TypeOne Time License
Description

Aurora Pharmaceutical generates revenue through the sale of veterinary pharmaceutical products across multiple animal health categories including antibiotics, pain management, parasite control, reproductive health, wound care, and stress management solutions for equine, porcine, poultry, bovine, and companion animals.

aurorapharmaceutical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 16 records shown
1EQUISUL-SDT®
Description

Sulfadiazine/Trimethoprim antibiotic for horses

aurorapharmaceutical.com
+15 more records
Core offering1 text field

Aurora Pharmaceutical develops, manufactures, and markets FDA-approved veterinary pharmaceutical products across multiple animal health categories, including antibiotics, pain management, parasiticides, reproductive health, wound care, and stress/hydration supplements. The portfolio covers equine, porcine, poultry, bovine, companion animals, and a limited human health line, with products sold through authorized sales representatives, a VET PORTAL for veterinarians, and direct contact channels primarily in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Daily Balance administration increased water consumption by 10% in horses
+3 more records
Product overview1 text field

Aurora Pharmaceutical is a veterinary pharmaceutical company offering a comprehensive portfolio of animal health products across six species categories (Equine, Porcine, Poultry, Bovine, Pets, and Human). The product line includes antibiotics (EQUISUL-SDT®, TiaGard®), pain management (EquiCoxib™), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. Lubricating Jelly), wound care (BARRIER® Wound Care), stress/hydration supplements (BALANCE®), vitamins (Oral-Pro® D3 Plus E), and general veterinary health products (PRO-TEC® antiseptics, CLARITY® Ultrasound Gel). The company operates with a focus on FDA-approved generic formulations and affordable alternatives to brand-name veterinary medications, supported by a state-of-the-art manufacturing facility in Northfield, Minnesota.

Product and service1 record
1EQUISUL-SDT® (Sulfadiazine/Trimethoprim)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Virbac is a French global animal health company producing pharmaceuticals, vaccines, and diagnostics for companion and livestock animals. Comparable as a multi-species veterinary pharmaceutical manufacturer serving similar end markets as Aurora, with broader geographic reach and larger product portfolio.

TypeDirect peer
Description

Huvepharma is a privately-held animal health and nutrition company with strong positions in livestock pharmaceuticals (especially anti-infectives and parasiticides) and poultry coccidiostats — directly comparable to Aurora's EpriGard, TiaGard, and CocciAid franchises.

TypeBroad incumbent
Description

Ceva is one of the largest independent veterinary pharmaceutical companies globally, with strong positions in poultry, swine, and companion animal health. Aurora's poultry (CocciAid) and swine (TiaGard, SwineMate) franchises overlap directly with Ceva's core therapeutic categories.

TypeBroad incumbent
Description

Phibro is a publicly-traded animal health and nutrition company with a broad portfolio including parasiticides, vaccines, and nutritional specialties for livestock and poultry. Highly comparable to Aurora's livestock and poultry product mix, though much larger and publicly listed.

TypeBroad incumbent
Description

Vetoquinol is a global veterinary pharmaceutical company with a broad portfolio of therapeutics, parasiticides, and specialty products across companion and production animals. Directly comparable to Aurora as a multi-species veterinary pharma manufacturer, though significantly larger and globally diversified.

TypeDirect peer
Description

Norbrook is a privately-held veterinary pharmaceutical manufacturer focused on generic and branded anti-infectives, parasiticides, and anti-inflammatories for livestock and companion animals. Highly comparable to Aurora's generic-first, multi-species manufacturing model, headquartered in Northern Ireland.

TypeDirect peer
Description

Bimeda is a private veterinary pharmaceutical manufacturer with strong positions in livestock, equine, and companion animal generics globally. The most directly comparable peer to Aurora in terms of business model (multi-species generics manufacturer), scale, and customer base, with significant overlap in parasiticides and antibiotics.

TypeBroad incumbent
Description

Dechra was a global veterinary pharmaceutical company specializing in companion animal and equine therapeutics, acquired by Elanco in 2024. Directly comparable to Aurora's equine franchise (EquiCoxib is a generic of EQUIOXX, marketed by Boehringer/Merial in Dechra's overlap space).

TypeBroad incumbent
Description

Elanco is one of the largest global animal health companies with deep franchises in livestock parasiticides (eprinomectin via Ivomecat Eprinex) and companion animal therapeutics. Aurora's EpriGard (eprinomectin pour-on) and EquiCoxib directly compete with Elanco's product portfolio.

TypeRegional player
Description

Kyoritsu Seiyaku is a Japanese veterinary pharmaceutical manufacturer specializing in livestock, poultry, and aquaculture therapeutics. Comparable to Aurora's livestock/poultry pharmaceutical manufacturing business model but operates primarily in Japan and Asia-Pacific rather than the U.S. market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurora Pharmaceutical

Veterinary Pharmaceuticalsaurorapharmaceutical.com

Aurora Pharmaceutical is a private, GMP-certified veterinary pharmaceutical manufacturer in Northfield, Minnesota that develops, produces, and sells FDA-approved generic and branded animal health products — including antibiotics, parasiticides, NSAIDs, reproductive drugs, wound care, and supplements — across equine, bovine, porcine, poultry, companion animal, and limited human markets in the United States.

What Aurora Pharmaceutical does

Aurora Pharmaceutical, Inc. is a privately-held veterinary pharmaceutical manufacturer headquartered at 1196 Highway 3 South, Northfield, Minnesota, that develops, manufactures, and distributes FDA-approved generic and branded animal health products across six species verticals: equine, porcine, poultry, bovine, companion animals, and a small human health line. The portfolio spans six therapeutic categories — antibiotics (e.g., EQUISUL-SDT®, TiaGard® 12.5%), pain management (EquiCoxib™/firocoxib), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. jelly), wound care and antiseptics (BARRIER® Wound Care, PRO-TEC® chlorhexidine cleansers), and stress/hydration supplements (BALANCE, ORAL-PRO® D3/E, oregano). The company operates GMP-certified manufacturing at its single Northfield facility and explicitly positions around first-generic FDA approvals (DectoGard as the first generic doramectin topical solution; EquiCoxib as the generic equivalent to EQUIOXX® Paste) and affordable alternatives to brand-name veterinary drugs.

The business model is direct-to-customer via an authorized field sales representative network that calls on livestock producers, veterinarians, and pet owners, supplemented by a self-serve VET PORTAL for veterinary professionals and phone/email ordering for smaller accounts. Products are sold primarily in the United States with differentiated labeling for international markets, and pricing is not publicly disclosed — customers must contact sales — but the company's value proposition centers on competitive pricing of FDA-approved formulations against branded incumbents. Customer segments are diversified across commercial livestock (beef, dairy, swine, poultry), the equine show/performance industry, companion animal owners and veterinary clinics, and a minor human health line (Oral-Pro® Pyrantel Pamoate).

Underlying technology is conventional small-molecule veterinary pharmaceutical formulation and manufacturing rather than biologs or novel modalities; proprietary features are described as advanced green formulation/delivery systems, multi-species formulation expertise, and quality-controlled manufacturing. Aurora has launched four products in 2024 (DectoGard, EquiCoxib, KLENTZ, TiaGard 12.5%), with leadership in place under CEO/President Michael Strobel and CFO Lori Happel, ~$7.46M in cumulative disclosed equity funding (2011 and 2015 rounds), 11–50 employees, and a stated DVM Student Scholarship Program scaling from $75K (2023) to $100K (2026).

Aurora Pharmaceutical firmographics

Firmographics
Name
Aurora Pharmaceutical
Legal name
Aurora Pharmaceutical, Inc.
Website
https://aurorapharmaceutical.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
Aurora Pharmaceutical is a private, GMP-certified veterinary pharmaceutical manufacturer in Northfield, Minnesota that develops, produces, and sells FDA-approved generic and branded animal health products — including antibiotics, parasiticides, NSAIDs, reproductive drugs, wound care, and supplements — across equine, bovine, porcine, poultry, companion animal, and limited human markets in the United States.
Ownership category
akta.pro rank

Aurora Pharmaceutical industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAMAEAM
Generic & Private-Label Veterinary Pharmaceuticals
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAF
Pain Management, Anesthesia & Critical Care Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYCRAOAKAD
Pet Pharmaceuticals & Veterinary Supply Distribution

Keywords

  • Veterinary pharmaceuticals
  • Animal health products
  • Livestock medications
  • Pet parasiticides
  • FDA-approved generics

Where Aurora Pharmaceutical is headquartered

Location

Headquarters

HQ city
Northfield
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aurora Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Veterinary Pharmaceutical Products: Aurora Pharmaceutical generates revenue through the sale of veterinary pharmaceutical products across multiple animal health categories including antibiotics, pain management, parasite control, reproductive health, wound care, and stress management solutions for equine, porcine, poultry, bovine, and companion animals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Aurora Pharmaceutical product offering

Product offering

Core offering

Aurora Pharmaceutical develops, manufactures, and markets FDA-approved veterinary pharmaceutical products across multiple animal health categories, including antibiotics, pain management, parasiticides, reproductive health, wound care, and stress/hydration supplements. The portfolio covers equine, porcine, poultry, bovine, companion animals, and a limited human health line, with products sold through authorized sales representatives, a VET PORTAL for veterinarians, and direct contact channels primarily in the United States.

Product overview

Aurora Pharmaceutical is a veterinary pharmaceutical company offering a comprehensive portfolio of animal health products across six species categories (Equine, Porcine, Poultry, Bovine, Pets, and Human). The product line includes antibiotics (EQUISUL-SDT®, TiaGard®), pain management (EquiCoxib™), parasiticides (DectoGard™, EpriGard®, REVOLT®, BARRIER®), reproductive products (ALTREN®, SwineMate®, OvuGel®, CLARITY® A.I. Lubricating Jelly), wound care (BARRIER® Wound Care), stress/hydration supplements (BALANCE®), vitamins (Oral-Pro® D3 Plus E), and general veterinary health products (PRO-TEC® antiseptics, CLARITY® Ultrasound Gel). The company operates with a focus on FDA-approved generic formulations and affordable alternatives to brand-name veterinary medications, supported by a state-of-the-art manufacturing facility in Northfield, Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

  • EQUISUL-SDT®: Sulfadiazine/Trimethoprim antibiotic for horses
  • EquiCoxib™
  • ALTREN®
  • SwineMate®
  • DectoGard™
  • EpriGard®
  • CocciAid®
  • TiaGard® 12.5%
  • REVOLT®
  • BARRIER®
  • KLENTZ™
  • OvuGel®
  • BALANCE
  • CLARITY®
  • PRO-TEC®
  • Oral-Pro®

Products and services

  • EQUISUL-SDT® (Sulfadiazine/Trimethoprim)

Quantifiable outcome

  • Daily Balance administration increased water consumption by 10% in horses
  • +3 more outcomes

Companies that use Aurora Pharmaceutical

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Aurora Pharmaceutical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aurora Pharmaceutical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Aurora Pharmaceutical competitors and assessment

Company assessment

Broad incumbents

  • Virbac: Virbac is a French global animal health company producing pharmaceuticals, vaccines, and diagnostics for companion and livestock animals. Comparable as a multi-species veterinary pharmaceutical manufacturer serving similar end markets as Aurora, with broader geographic reach and larger product portfolio.
  • Ceva Santé Animale: Ceva is one of the largest independent veterinary pharmaceutical companies globally, with strong positions in poultry, swine, and companion animal health. Aurora's poultry (CocciAid) and swine (TiaGard, SwineMate) franchises overlap directly with Ceva's core therapeutic categories.
  • Phibro Animal Health: Phibro is a publicly-traded animal health and nutrition company with a broad portfolio including parasiticides, vaccines, and nutritional specialties for livestock and poultry. Highly comparable to Aurora's livestock and poultry product mix, though much larger and publicly listed.
  • Vetoquinol: Vetoquinol is a global veterinary pharmaceutical company with a broad portfolio of therapeutics, parasiticides, and specialty products across companion and production animals. Directly comparable to Aurora as a multi-species veterinary pharma manufacturer, though significantly larger and globally diversified.
  • Dechra Pharmaceuticals (Elanco): Dechra was a global veterinary pharmaceutical company specializing in companion animal and equine therapeutics, acquired by Elanco in 2024. Directly comparable to Aurora's equine franchise (EquiCoxib is a generic of EQUIOXX, marketed by Boehringer/Merial in Dechra's overlap space).
  • Elanco Animal Health: Elanco is one of the largest global animal health companies with deep franchises in livestock parasiticides (eprinomectin via Ivomecat Eprinex) and companion animal therapeutics. Aurora's EpriGard (eprinomectin pour-on) and EquiCoxib directly compete with Elanco's product portfolio.

Direct peers

  • Huvepharma: Huvepharma is a privately-held animal health and nutrition company with strong positions in livestock pharmaceuticals (especially anti-infectives and parasiticides) and poultry coccidiostats — directly comparable to Aurora's EpriGard, TiaGard, and CocciAid franchises.
  • Norbrook: Norbrook is a privately-held veterinary pharmaceutical manufacturer focused on generic and branded anti-infectives, parasiticides, and anti-inflammatories for livestock and companion animals. Highly comparable to Aurora's generic-first, multi-species manufacturing model, headquartered in Northern Ireland.
  • Bimeda: Bimeda is a private veterinary pharmaceutical manufacturer with strong positions in livestock, equine, and companion animal generics globally. The most directly comparable peer to Aurora in terms of business model (multi-species generics manufacturer), scale, and customer base, with significant overlap in parasiticides and antibiotics.

Regional players

  • Kyoritsu Seiyaku: Kyoritsu Seiyaku is a Japanese veterinary pharmaceutical manufacturer specializing in livestock, poultry, and aquaculture therapeutics. Comparable to Aurora's livestock/poultry pharmaceutical manufacturing business model but operates primarily in Japan and Asia-Pacific rather than the U.S. market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Aurora Pharmaceutical social profiles

Digital presence

Aurora Pharmaceutical compliance and trust

Trust signal

Compliance1 record

Aurora Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurora Pharmaceutical leadership team

Management profile

Number of profiles

Profiles3 records

Aurora Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurora Pharmaceutical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Pharmaceutical

What does Aurora Pharmaceutical do?

Aurora Pharmaceutical develops, manufactures, and markets FDA-approved veterinary pharmaceutical products across multiple animal health categories, including antibiotics, pain management, parasiticides, reproductive health, wound care, and stress/hydration supplements. The portfolio covers equine, porcine, poultry, bovine, companion animals, and a limited human health line, with products sold through authorized sales representatives, a VET PORTAL for veterinarians, and direct contact channels primarily in the United States.

Is Aurora Pharmaceutical a public or private company?

Aurora Pharmaceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aurora Pharmaceutical founded?

Aurora Pharmaceutical was founded in 2007. It employs 51 to 100 people.

Where is Aurora Pharmaceutical based?

Aurora Pharmaceutical is headquartered in Northfield, United States, in the North America region.

How does Aurora Pharmaceutical make money?

One revenue line is on record: veterinary Pharmaceutical Products.

Who are Aurora Pharmaceutical's main competitors?

Broad incumbents on record are Virbac, Ceva Santé Animale, Phibro Animal Health, Vetoquinol, Dechra Pharmaceuticals (Elanco) and Elanco Animal Health. Direct peers are Huvepharma, Norbrook and Bimeda. Kyoritsu Seiyaku is listed as a regional player.

Does Aurora Pharmaceutical have an API?

No public API is recorded for Aurora Pharmaceutical.

What industry is Aurora Pharmaceutical in?

Aurora Pharmaceutical's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAM, Generic & Private-Label Veterinary Pharmaceuticals, with a secondary code of HLAMAEAB, Livestock & Production Animal Therapeutics (Rx). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
National Hog FarmerAurora Pharmaceutical receives FDA approval on SwineMateAurora Pharmaceutical received FDA approval for SwineMate, an altrenogest solution used to synchronize estrus in sexually mature gilts. The product is manufactured in Northfield, Minnesota, and distributed through major distributors across the United States. This approval enables Aurora to market the treatment for individual or group administration over a 14-day period.PR NewswireAurora Pharmaceutical Awards $90,000 in Scholarships to 28 Veterinary Students Across the NationAurora Pharmaceutical awarded $90,000 in scholarships to 28 third-year veterinary students across the country. The awards include 22 scholarships of $2,500, five of $5,000, and one top scholarship of $10,000, selected through a competitive process. The program, now in its fifth year, continues to support students committed to veterinary medicine.MorningstarAurora Pharmaceutical Delivers on FDA-Approved Generic for Equine Pain ReliefAurora Pharmaceutical announced EquiCoxib, an FDA-approved generic of Equioxx, for equine osteoarthritis pain. The liquid formulation allows once-daily oral dosing, offering a cost-effective alternative to the brand-name product. The product is available by prescription through licensed veterinarians.PR NewswireAurora Pharmaceutical Appoints Stephanie Hastings as Director of MarketingAurora Pharmaceutical announced the appointment of Stephanie Hastings as its new Director of Marketing. Hastings brings over 15 years of experience in communications, public relations, and marketing across regulated health, wellness, and agriculture industries. CEO Dr. Mike Strobel stated her strategic insight and leadership will support the company's growth goals and market position in the animal health sector.PR NewswireVersatile CBD Products Drive Market Growth with 27% CAGR Forecasted Through 2023, Addressing a Range of Health and Wellness NeedsResearchAndMarkets.com has published a market report forecasting the global Cannabidiol (CBD) market to reach US$6.17 billion by 2023, growing at a 27% CAGR. The report highlights that North America leads the market due to regulatory approvals and major player presence, with significant growth drivers including medical applications and increasing government legalization. Key industry participants identified in the fragmented market include Canopy Growth Corporation, Tilray Brand Inc., Jazz Pharmaceuticals PLC, and Aurora Pharmaceutical, Inc.